2023
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
Kondo T, Butt J, Curtain J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure 2023, 16: e010898. PMID: 37886880, DOI: 10.1161/circheartfailure.123.010898.Peer-Reviewed Original ResearchMeSH KeywordsAtrial FibrillationHeart FailureHeart Failure, SystolicHeart RateHumansStroke VolumeVentricular Dysfunction, LeftVentricular Function, LeftConceptsLeft ventricular ejection fractionReduced ejection fractionVentricular ejection fractionPatient-level pooled analysisBenefit of dapagliflozinEjection fractionHeart failureAtrial fibrillationBaseline heart rateSinus rhythmHeart ratePrimary outcomeDAPA-HFCardiovascular deathPooled analysisHR rangeEfficacy of dapagliflozinEffect of dapagliflozinHeart failure phenotypeHigher heart rateCardiovascular eventsHazard ratioHigh riskFailure phenotypePatientsQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
2018
Letter by Adabag et al Regarding Article, “Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure”
Adabag S, Wininger M, Singh SN. Letter by Adabag et al Regarding Article, “Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure”. Circulation 2018, 137: 2188-2189. PMID: 29760231, DOI: 10.1161/circulationaha.117.032906.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsDefibrillators, ImplantableElectric CountershockHeart Failure, SystolicHumansPrimary Prevention
2017
Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient
DeVore AD, Alenezi F, Krishnamoorthy A, Ersboll M, Samsky MD, Schulte PJ, Patel CB, Rogers JG, Milano CA, Velazquez EJ, Khouri MG. Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient. Clinical Transplantation 2017, 31: e12961. PMID: 28294407, DOI: 10.1111/ctr.12961.Peer-Reviewed Original ResearchConceptsLV global longitudinal strainLeft ventricular ejection fractionGlobal longitudinal strainMedian left ventricular ejection fractionSystolic functionLongitudinal strainLV systolic dysfunctionMyocardial systolic performancePost-transplant outcomesLV systolic functionVentricular ejection fractionDonor-recipient pairsMyocardial deformation analysisAllograft dysfunctionCardiac allograftsCause hospitalizationSystolic dysfunctionPretransplant levelsEjection fractionSystolic performanceCorresponding recipientsClinical implicationsRecipientsEchocardiogramFurther studiesImpaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristics
2016
Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support
Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, Ilkayeva OR, Bowles DE, Patel CB, Milano CA, Rogers JG, Felker GM, O’Connor C, Shah SH, Kraus WE. Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. Journal Of The American College Of Cardiology 2016, 67: 291-299. PMID: 26796394, PMCID: PMC5429585, DOI: 10.1016/j.jacc.2015.10.079.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarnitineDisease ProgressionEnergy MetabolismExercise TherapyFemaleHeart Failure, SystolicHeart-Assist DevicesHospital MortalityHumansMaleMass SpectrometryMiddle AgedNorth CarolinaOutcome Assessment, Health CarePrognosisReproducibility of ResultsSeverity of Illness IndexStatistics as TopicConceptsEnd-stage heart failureSystolic heart failureHeart failureMechanical circulatory supportHF patientsClinical outcomesCirculatory supportEnd-stage systolic heart failureChronic systolic HF patientsLeft ventricular assist device placementLong-term mechanical circulatory supportVentricular assist device placementPeak VO2 levelsChronic HF patientsSystolic HF patientsAdverse clinical outcomesClinical trial outcomesLong-chain acylcarnitinesAssociations of metabolitesFrozen plasma samplesMechanical circulatoryCardiovascular deathCause hospitalizationCause mortalityLVAD group
2013
Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 525-533. PMID: 24021697, DOI: 10.1161/circoutcomes.111.000079.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCaliforniaCardiotonic AgentsChi-Square DistributionDigoxinDisease ProgressionDrug Therapy, CombinationFemaleGuideline AdherenceHealth Maintenance OrganizationsHeart Failure, SystolicHospitalizationHumansIncidenceMaleMiddle AgedMultivariate AnalysisPractice Guidelines as TopicProportional Hazards ModelsRisk FactorsSex FactorsTime FactorsTreatment OutcomeConceptsIncident systolic heart failureSystolic heart failureSafety of digoxinΒ-blocker useDigoxin useHeart failureHF hospitalizationConcurrent β-blocker useSymptomatic systolic heart failureKaiser Permanente Northern CaliforniaHF disease severityOptimal medical therapyRisk of deathMedical therapyMultivariable analysisContemporary cohortCox regressionClinical guidelinesMedical historyHigh riskHospitalizationHigh mortalityPatientsDisease severityTrial dataInfluence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease
Doenst T, Cleland JG, Rouleau JL, She L, Wos S, Ohman EM, Krzeminska-Pakula M, Airan B, Jones RH, Siepe M, Sopko G, Velazquez EJ, Racine N, Gullestad L, Filgueira JL, Lee KL. Influence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease. Circulation Heart Failure 2013, 6: 443-450. PMID: 23515275, PMCID: PMC3721746, DOI: 10.1161/circheartfailure.112.000130.Peer-Reviewed Original ResearchMeSH KeywordsAgedComorbidityCoronary Artery BypassCoronary Artery DiseaseCross-Over StudiesDisease ProgressionFemaleHeart Failure, SystolicHumansMaleMiddle AgedConceptsHeart failureCoronary artery bypass graft surgeryIschemic Heart Failure (STICH) trialPatient/family decisionArtery bypass graft surgeryImpact of CABGBypass graft surgeryHeart Failure TrialMultivariable Cox modelSystolic heart failureCoronary artery diseaseIschemic heart diseaseAcute decompensationGraft surgeryProgressive symptomsArtery diseaseMedical therapySurgical treatmentFailure TrialPatient populationHeart diseaseCABGCommon reasonCox modelPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply